Overview

VX-770 for the Treatment of Chronic Bronchitis

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This research study will test how well a new drug affects bronchiectasis or chronic bronchitis. The new drug, Ivacaftor (KALYDECO), is a drug that has recently been approved by the U.S. Food and Drug Administration (FDA) for patients with a lung disease called Cystic Fibrosis (CF). It has not been approved for use in patients with bronchiectasis or chronic bronchitis.

Phase:

Phase 4

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Ivacaftor